Series B · BiotechVaderis Therapeutics: Series BDevelops an oral AKT inhibitor for hereditary hemorrhagic telangiectasiaPublished Oct 4, 2026By RoundOS Funding deskFunding historyAug 11, 2026Series B · This round$152MSourcesprnewswire.com↗
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200MPrivate financing · Oct 23, 2026
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237MSeries E · Oct 23, 2026
Knowledge WorkTokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.¥4.8BSeries C debt second close · Oct 23, 2026
Cognitive CreditCognitive Credit provides corporate credit data, financial models and AI analysis tools for investment banks and asset managers.$40MStrategic growth investment · Oct 22, 2026